PSA 8.4 with a 120 mL prostate: does this mean prostate cancer? | Dr Dilanka De Silva

Who is this article for?

This article is for men who have urinary symptoms and a high PSA level and are worried that they may have prostate cancer.

If you are reading this late at night, the first thing to understand is that a high PSA level does not automatically mean cancer.

The size of your prostate can significantly change what the PSA result means.

A patient’s story

I recently assessed a 74-year-old gentleman who had increasing difficulty passing urine, a reduced urinary stream and dribbling.

His PSA was elevated at 8.4 ng/mL.

His symptoms were compatible with benign prostatic hyperplasia, which simply means non-cancerous enlargement of the prostate and becomes increasingly common as men get older.

However, because his PSA was elevated, it was still important to investigate properly and exclude clinically significant prostate cancer.

His multiparametric MRI showed that his prostate was markedly enlarged, measuring 120 mL.

This was a crucial finding when interpreting his PSA.

The diamond answer

A PSA of 8.4 should not be ignored.

But it does not automatically mean prostate cancer.

For this gentleman:

PSA = 8.4 ng/mL
Prostate volume = 120 mL

His PSA density was:

8.4 ÷ 120 = 0.07 ng/mL/mL

This is relatively reassuring and suggests that his markedly enlarged prostate may explain much of the PSA elevation.

However, PSA density cannot diagnose or completely exclude prostate cancer by itself.

The PI-RADS score, PSA trend, MRI findings and individual risk factors still matter.

Why this matters

PSA is produced by normal prostate tissue as well as prostate cancer cells.

A large benign prostate can therefore produce considerably more PSA than a small prostate.

A PSA of 8.4 coming from a smaller prostate may raise more concern than the same PSA coming from a prostate measuring 120 mL.

This is why I do not interpret PSA as an isolated number.

What should be assessed first?

Before assuming that an elevated PSA represents cancer, I consider several important questions:

1. Could infection, inflammation or urinary retention have temporarily increased the PSA?
2. Is there a previous PSA result showing whether it is stable or rising?
3. Is the patient taking medicines such as finasteride or dutasteride that can lower PSA?
4. Does the MRI show anything suspicious?
5. Is there a significant family history or inherited risk of prostate cancer?

A digital rectal examination can sometimes identify a hard area, asymmetry or irregularity and may form part of specialist assessment.

However, a normal examination cannot completely exclude prostate cancer.

Why I use multiparametric MRI

A high-quality multiparametric MRI is now an important investigation when an elevated PSA requires further assessment.

The MRI gives us three particularly useful pieces of information:

1. The PI-RADS score
2. The location and size of any suspicious area
3. An estimate of the prostate volume

The PSA and relevant clinical information should also be available when the MRI is interpreted.

Current Australian guidance recommends mpMRI before deciding whether a prostate biopsy is required.

How large is a normal prostate at different ages?

The prostate usually becomes larger as a man gets older.

However, there is no single “normal” prostate size for a particular age.

One study involving 3,568 Filipino men reported the following average prostate volumes:

These are population averages from one Filipino study—not strict normal limits for every man.

Our patient was 74 years old and his prostate measured 120 mL.

That is approximately three times the average reported for men aged 70–79 in that particular study.

This confirms that his prostate was very substantially enlarged.

It supports benign prostatic enlargement as an important explanation for his urinary symptoms, although prostate size alone cannot exclude cancer.

What is PSA density?

PSA density answers one simple question:

Is the PSA unusually high for the size of this particular prostate?

It is calculated by dividing the PSA by the prostate volume:

PSA density = PSA ÷ prostate volume

For this gentleman:

8.4 ÷ 120 = 0.07

His PSA density was therefore approximately 0.07 ng/mL/mL.

This is relatively reassuring.

European guidance notes that clinically significant prostate cancer was found in only around 4 in every 100 men with a PSA density below 0.09 ng/mL/mL in published data.

That does not mean a PSA density of 0.07 guarantees that cancer is absent.

It means the result is considerably more reassuring than the PSA of 8.4 appears when viewed by itself.

Why the prostate measurement changes everything

The same PSA can have a very different interpretation depending on prostate size.

The PSA remains 8.4 in every example.

Only the prostate volume changes.

This demonstrates why an accurate prostate-volume measurement can substantially change how a high PSA level is interpreted.

Looking only at the PSA may create unnecessary anxiety and, in some situations, lead to investigation that might otherwise be avoided.

When is PSA density concerning?

PSA density is not a perfect test, and there is no single number that can diagnose prostate cancer.

In general, risk increases as PSA density rises.

Values below approximately 0.09–0.10 are relatively reassuring, while values above 0.10–0.15 require progressively more attention depending on the MRI and other risk factors.

The threshold of 0.15 is particularly useful when the MRI result is PI-RADS 3.

Current Australian guidance recommends offering biopsy when a PI-RADS 3 lesion is accompanied by a PSA density of 0.15 or higher.

Conversely, selected men with PI-RADS 3 and PSA density below 0.15 may be able to avoid immediate biopsy after appropriate clinical assessment.

So I would not use 0.15 as a universal “cancer cut-off.”

What is the PI-RADS score?

PI-RADS is a five-point MRI scale estimating the likelihood of clinically significant prostate cancer.

PI-RADS 5 carries the highest level of MRI suspicion.

However, MRI cannot independently diagnose prostate cancer.

A biopsy is generally required before prostate cancer can be confirmed.

What does the research show?

The PROMIS study

PROMIS helped establish the value of multiparametric MRI before a first prostate biopsy.

MRI detected clinically significant prostate cancer with a sensitivity of approximately 93%.

Importantly, about 27 in every 100 men had a negative MRI and could potentially have avoided an immediate standard biopsy.

However, MRI was not perfect. Some clinically significant cancers were still present despite a negative MRI.

The PRECISION trial

PRECISION compared an MRI-directed pathway with traditional systematic biopsy.

Clinically significant prostate cancer was detected in approximately:

• 38 in every 100 men using the MRI-directed pathway; compared with
• 26 in every 100 men undergoing standard systematic biopsy.

In addition, 28 in every 100 men in the MRI pathway had a non-suspicious MRI and therefore did not undergo biopsy.

The MRI pathway also detected fewer low-risk cancers that may never have caused harm.

These studies help explain why MRI now plays such an important role before prostate biopsy.

Interpretation

This gentleman’s PSA of 8.4 required proper investigation.

However, the MRI showed that his prostate measured 120 mL.

Once the PSA was considered relative to the prostate volume, his PSA density was only 0.07.

That is substantially more reassuring than the PSA result initially appears.

Significant benign prostate enlargement is therefore an important possible explanation for both his urinary symptoms and his elevated PSA.

However, I would still want to review the PI-RADS score, previous PSA results, MRI findings and individual prostate-cancer risk before deciding whether biopsy is required.

What usually happens next?

If the MRI is PI-RADS 1–2, the PSA density of 0.07 may support monitoring rather than immediate biopsy if the remaining assessment is reassuring.

If the MRI is PI-RADS 3, the finding is uncertain. In this patient, the PSA density of 0.07 is well below the Australian threshold of 0.15 used to help guide the biopsy decision.

If the MRI is PI-RADS 4–5, the suspicious MRI finding becomes more important. Urology review and prostate biopsy would generally be offered.

When biopsy is required, an MRI-targeted biopsy combined with systematic sampling may be recommended, with a transperineal approach now generally preferred in Australia because of its lower infection risk.

The final decision should still be individualised.

What surprised me?

A PSA of 8.4 can sound frightening when a patient first sees the number on a blood-test report.

But another number—120 mL—can substantially change its meaning.

The lesson is simple.

Do not ask only:

“Is my PSA high?”

The better question is:

“Is my PSA high for the actual size of my prostate, and what does my MRI show?”

Key takeaways

• A high PSA level does not automatically mean prostate cancer. Prostate size, PSA trend and other causes of PSA elevation all matter.
• A PSA of 8.4 with a 120 mL prostate gives a PSA density of approximately 0.07, which is relatively reassuring but does not completely exclude clinically significant cancer.
• The PI-RADS score and PSA density should be interpreted together. A PSA-density threshold of 0.15 is particularly useful when deciding what to do with a PI-RADS 3 MRI.
• The decision to proceed to biopsy should be based on the complete clinical picture rather than one PSA number alone.

Key evidence

1. Lavadia ACD, Reyes BJB, Gumiran TAF, Bandong IS. Age-stratified mean values of prostate volume among Filipino males in a tertiary hospital: a single center study. Philippine Journal of Urology. 2022;32(1). Accessed October 1, 2026. https://pjuonline.com/index.php/pju/article/view/138
2. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822. doi:10.1016/S0140-6736(16)32401-1
3. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993
4. Prostate Cancer Foundation of Australia. 2026 Guidelines for the Early Detection of Prostate Cancer in Australia. Prostate Cancer Foundation of Australia; 2026. Published May 18, 2026. Accessed October 1, 2026. 2026 Guidelines for the Early Detection of Prostate Cancer in Australia
5. European Association of Urology. Diagnostic evaluation. EAU Guidelines on Prostate Cancer. 2026. Accessed October 1, 2026. EAU Guidelines on Prostate Cancer: Diagnostic Evaluation

Frequently asked questions

1. Does a PSA of 8.4 mean I have prostate cancer?

No. PSA can rise because of prostate cancer, but it can also rise because of benign prostate enlargement, inflammation, infection or urinary retention.

The prostate volume, MRI findings and PSA trend can substantially change how the result is interpreted.

2. Is a 120 mL prostate very large?

Yes. It represents substantial prostate enlargement.

For comparison, one study of Filipino men aged 70–79 reported an average prostate volume of approximately 40 mL, although prostate size varies considerably between individuals and populations.

3. Is a PSA density of 0.07 reassuring?

It is relatively reassuring because the amount of PSA is low compared with the size of the prostate.

However, no PSA-density value can completely rule out clinically significant prostate cancer.

4. Does a PI-RADS 3 MRI always require biopsy?

No.

Current Australian guidance suggests that selected men with PI-RADS 3 and PSA density below 0.15 may not require immediate biopsy after clinical assessment.

5. What happens with a PI-RADS 4 or 5 MRI?

These findings are more suspicious for clinically significant prostate cancer.

Current Australian guidance recommends offering prostate biopsy, with the final decision based on the individual clinical situation.

About Dr Dilanka De Silva

Dr Dilanka De Silva is a Melbourne-based Medical Oncologist and Cancer Genetics Physician with experience in precision oncology, prostate cancer assessment, hereditary cancer risk and complex cancer second opinions.

He completed fellowship training at Memorial Sloan Kettering Cancer Center in New York and reviews Australian and international patients through Sloan Maccallum Cancer Care, including patients and families in Sri Lanka, the Maldives, Indonesia and the Philippines.

Dr Dilanka De Silva
MBBS, MRCP(UK), MRCP(UK SCE Oncology), FRACP, PhD
Medical Oncologist & Cancer Genetics Physician
Memorial Sloan Kettering Cancer Center Fellow (New York, USA)